Publication | Closed Access

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Lymphoid NeoplasiaMedicineFollicular LymphomaSubcutaneous RituximabIntravenous RituximabLymphatic DiseaseOncologyRadiation Oncology